<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05015621</url>
  </required_header>
  <id_info>
    <org_study_id>2021-012-00CH1</org_study_id>
    <nct_id>NCT05015621</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma</brief_title>
  <official_title>A Phase 3, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Surufatinib Plus Toripalimab Versus FOLFIRI as a Secondline Treatment in Patients With Advanced Neuroendocrine Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Surufatnib combined with Toripalimab compared with FOLFIRI in the&#xD;
      treatment of advanced neuroendocrine carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, open-label, multicenter, phase III clinical study designed&#xD;
      to evaluate the efficacy and safety of surufatnib combined with toripalimab compared with&#xD;
      FOLFIRI in patients with advanced neuroendocrine carcinoma who have progression of disease or&#xD;
      intolerable toxicity after previous 1st-line chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of first dose of study drug until withdrawal of consent or death (up to approximately 2 years)</time_frame>
    <description>Duration from the date of initial treatment to the date of death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) (RECIST1.1)</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anticancer therapy (up to approximately 2 years)</time_frame>
    <description>A duration from the date of initial treatment to disease progression or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)(RECIST1.1)</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anticancer therapy(up to approximately 2 years)]</time_frame>
    <description>The incidence of confirmed complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)(RECIST1.1)</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 2 years)]</time_frame>
    <description>Duration from the first time reported partial response or complete response to the first time of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)(RECIST1.1)</measure>
    <time_frame>From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 2 years)]</time_frame>
    <description>Proportion of patients whose tumor volume control (reduced or enlarged) reaches a predetermined value and can maintain a minimum time limit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1</measure>
    <time_frame>Baseline (before the randomization)</time_frame>
    <description>To evaluate the relationship between the efficacy and tumor biomarkers of PD-L1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ki67</measure>
    <time_frame>Baseline (before the randomization)</time_frame>
    <description>To evaluate the relationship between the efficacy and tumor biomarkers of ki67</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>From the within 7 days prior to the initiation of treatment to 30 days after the last administration</time_frame>
    <description>The changes in health-related quality of life (HRQoL) score from baseline and the time to deterioration of symptoms (TTD) as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Advanced Neuroendocrine Carcinoma</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>all subjects will receive study treatment in 21-day cycle, Surufatinib 250mg, QD and Toripalimab, 240mg, IV drip, Q3W, D1, the treatment will continue until one of the following conditions occurs: progression of disease, death, intolerable toxicity, or the end of study treatment (as other criteria specified in the protocol are met), whichever occurs first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FOLFIRI group subjects will receive study treatment in 14- day cycle, Irinotecan: 180 mg/m^2, iv drip over 30～90 minutes, on Day 1; Calcium folinate: 400 mg/m^2, iv drip for about 2 hours, given upon completion of infusion of Irinotecan on Day 1; 5-FU: 400 mg/m^2, iv bolus, given upon completion of infusion of Calcium folinate on Day 1, followed by 2400 mg/m^2 continuously iv drip for 46～48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib plus Toripalimab</intervention_name>
    <description>Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>HMPL-012 plus JS001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil, Calcium folinate and Irinotecan</intervention_name>
    <description>Irinotecan 180 mg/m^2, Calcium folinate 400 mg/m^2, 5-FU total 2800 mg/m^2 will be administrated once two weeks.</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>FOLFIRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who included in this study must fulfil all of the following criteria:&#xD;
&#xD;
               1. Fully aware of this study and voluntary to sign the informed consent form (the&#xD;
                  informed consent form must be signed before any trial-specific procedure is&#xD;
                  performed);&#xD;
&#xD;
               2. Aged 18~75 years (inclusive);&#xD;
&#xD;
               3. Histologically or cytologically confirmed, unresectable, locally advanced or&#xD;
                  metastatic neuroendocrine carcinoma&#xD;
&#xD;
               4. Patients with neuroendocrine carcinoma who have failed previous platinum-based&#xD;
                  1st-line chemotherapy&#xD;
&#xD;
               5. ECOG performance status of 0 or 1 ;&#xD;
&#xD;
               6. Having clear measurable lesions as defined by RECIST v1.1;&#xD;
&#xD;
               7. Patients who agree to provide tumor specimens for pathological type review and&#xD;
                  biomarkers detection;&#xD;
&#xD;
               8. Patients with adequate bone marrow, liver and kidney organ functions whose&#xD;
                  laboratory tests within 7 days before the first dose meet the following&#xD;
                  requirements:&#xD;
&#xD;
                    1. Absolute neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L and&#xD;
                       hemoglobin ≥90 g/dL (without blood transfusion or use of blood products for&#xD;
                       correction within 14 days prior to laboratory examination, and without use&#xD;
                       of granulocyte colony stimulating factor or other hematopoietic stimulating&#xD;
                       factor for correction within 7 days prior to laboratory examination);&#xD;
&#xD;
                    2. Serum total bilirubin ≤1.5 × upper limit of normal (ULN);&#xD;
&#xD;
                    3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 ×&#xD;
                       ULN in the absence of liver metastases; ALT and AST ≤5 × ULN in the presence&#xD;
                       of liver metastases.&#xD;
&#xD;
                    4. Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min&#xD;
                       (calculated according to the Cockcroft-Gault formula, see Appendix 3);&#xD;
&#xD;
                    5. Routine urinalysis showing urine protein &lt; 2+; in case of urine protein ≥&#xD;
                       2+, 24-hour urine protein (quantitative) should be &lt;1g;&#xD;
&#xD;
                    6. International normalized ratio (INR) ≤ 1.5 and activated partial&#xD;
                       thromboplastin time (APTT) ≤1.5 × ULN.&#xD;
&#xD;
               9. Estimated survival ≥ 12 weeks;&#xD;
&#xD;
              10. Females of childbearing potential must have a negative serum pregnancy test&#xD;
                  within 7 days prior to the first dose. Male or female patients of childbearing&#xD;
                  potential volunteer to use effective contraceptive methods during the study and&#xD;
                  within 90 days after last administration of the study drug, such as double&#xD;
                  barrier contraception, condoms, oral or injectable contraceptives, intrauterine&#xD;
                  contraceptive device, etc. All female patients will be considered to be of&#xD;
                  childbearing potential unless they are naturally postmenopausal, underwent&#xD;
                  artificial menopause, or are surgically sterile (e.g., hysterectomy, bilateral&#xD;
                  adnexectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects must be excluded from this study when any one of the following criteria is&#xD;
             met:&#xD;
&#xD;
               1. Toxicities associated with previous anti-tumor treatment do not return to ≤CTCAE&#xD;
                  grade 1, except for alopecia and peripheral neurotoxicity (≤ CTCAE grade 2 )&#xD;
                  caused by Oxaliplatin;&#xD;
&#xD;
               2. Presence of other malignancies in the past 5 years (except for basal cell&#xD;
                  carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the&#xD;
                  cervix, which were effectively controlled);&#xD;
&#xD;
               3. Presence of central nervous system (CNS) metastases in screening period;&#xD;
&#xD;
               4. Use of approved systematic anti-tumor therapy within 4 weeks prior to the first&#xD;
                  dose, including chemotherapy, biotherapy, targeted therapy (the washout period of&#xD;
                  small molecular targeted drugs lasts 2 weeks or 5 half-lives, whichever is&#xD;
                  shorter), hormone therapy, treatments with traditional Chinese medicine (for&#xD;
                  patients receiving treatments with traditional Chinese medicine with clear&#xD;
                  anti-tumor indications, for anti-tumor indications clearly specified in the&#xD;
                  package insert, one-week washout period prior to the first dose is acceptable),&#xD;
                  etc.;&#xD;
&#xD;
               5. Use of radical radiotherapy (including radiotherapy for more than 25% of the bone&#xD;
                  marrow) within 4 weeks before the first dose; brachytherapy (e.g. radioactive&#xD;
                  particle implantation) within 60 days prior to the first dose; palliative&#xD;
                  radiotherapy for bone metastases within 1 week before the first dose;&#xD;
&#xD;
               6. Previous use of anti (PD-1), anti-PD-L1, anti-PD-L2 or CTLA-4 antibody or any&#xD;
                  other antibody acting on T cell co-stimulatory or checkpoint pathways&#xD;
&#xD;
               7. Previous use of vascular endothelial growth factor (VEGF)/vascular endothelial&#xD;
                  growth factor receptor (VEGFR) targeted therapy;&#xD;
&#xD;
               8. Previous therapy with Irinotecan;&#xD;
&#xD;
               9. Having abnormal thyroid function with symptoms ongoing or requiring treatment at&#xD;
                  screening ;&#xD;
&#xD;
              10. Use of immunosuppressant within 4 weeks prior to the first dose, not including&#xD;
                  local glucocorticoid via nasal spray, inhalation or other routes or systemic&#xD;
                  glucocorticoid at physiological dose (i.e., no more than 10mg/day of prednisone&#xD;
                  or equivalent dose), temporary use of glucocorticoid for treatment of dyspnea&#xD;
                  resulted from asthma, chronic obstructive pulmonary disease is allowed, and&#xD;
                  preventive use of corticosteroid to avoid allergic reactions is allowed&#xD;
&#xD;
              11. Patients with any active autoimmune disorders requiring systematic treatment or a&#xD;
                  history of autoimmune disease in the past 2 years,&#xD;
&#xD;
              12. Use of systemic immune stimulants within 4 weeks prior to the first dose;&#xD;
&#xD;
              13. Vaccination of any live or attenuated live vaccine within 4 weeks prior to the&#xD;
                  first dose or during the study.&#xD;
&#xD;
              14. Patients having received major surgical operation within 4 weeks prior to the&#xD;
                  first dose .&#xD;
&#xD;
              15. Uncontrollable malignant hydrothorax, ascites or pericardial effusion ;&#xD;
&#xD;
              16. Patients who currently have hypertension that cannot be controlled by medication.&#xD;
&#xD;
              17. Patients who currently have any disease or condition that affects drug&#xD;
                  absorption, or patient who cannot take the drug orally;&#xD;
&#xD;
              18. Use of CYP3A potent or moderate inducers during the administration of concomitant&#xD;
                  medications or within 2 weeks or 5 half-lives (whichever is longer) prior to the&#xD;
                  first dose;&#xD;
&#xD;
              19. Patients who currently have gastric and duodenal active ulcer, ulcerative&#xD;
                  colitis, or active bleeding in the unresected tumor, or serious gastrointestinal&#xD;
                  disorders , or other conditions that may cause haemorrhage of digestive tract or&#xD;
                  perforation&#xD;
&#xD;
              20. Patients with evidence or history of obvious bleeding tendency within 2 months&#xD;
                  prior to the first dose&#xD;
&#xD;
              21. Arterial thrombosis or deep venous thrombosis occurred within 6 months prior to&#xD;
                  the first dose; or stroke events and/or transient ischemic attacks occurred&#xD;
                  within 12 months.&#xD;
&#xD;
              22. Clinically significant cardiovascular disorder,&#xD;
&#xD;
              23. Presence of clinically significant electrolyte abnormality judged by the&#xD;
                  investigator;&#xD;
&#xD;
              24. Patients with active infection or fever of unknown origin during screening and&#xD;
                  prior to the first dose (body temperature &gt;38.5°C);&#xD;
&#xD;
              25. Patients with active tuberculosis (TB), receiving anti-tuberculosis therapy&#xD;
                  currently or within one year prior to the first dose;&#xD;
&#xD;
              26. Patients with pulmonary fibrosis, interstitial pneumonia, pneumoconiosis,&#xD;
                  radiation pneumonitis, drug-related pneumonia, serious lung function impairment&#xD;
                  that may interfere with the detection and management of suspected drug-related&#xD;
                  pulmonary toxicities; radiation pneumonitis in the area of radiotherapy is&#xD;
                  allowed;&#xD;
&#xD;
              27. Human immunodeficiency virus (HIV) antibody positive;&#xD;
&#xD;
              28. Patients with known history of clinically significant liver diseases, including&#xD;
                  those infected with active viral hepatitis [HBV DNA &gt; 1 × 104 copies/mL or &gt; 2000&#xD;
                  IU/mL when hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody&#xD;
                  (HbcAb) is positive; patients with known positive hepatitis C virus antibody (HCV&#xD;
                  Ab) and HCV RNA &gt; 1 × 103 copies/mL], or other hepatitis, including moderate and&#xD;
                  severe hepatic cirrhosis with a clinical significance;&#xD;
&#xD;
              29. Use of clinical drug treatment which has not been approved or marketed in China&#xD;
                  within 4 weeks prior to the first dose;&#xD;
&#xD;
              30. Pregnant (positive pregnancy test prior to administration) or lactating women;&#xD;
&#xD;
              31. Patients with known allergy to any component of toripalimab, surufatnib or&#xD;
                  Irinotecan, fluorouracil and calcium folinate preparations, or previous history&#xD;
                  of serious allergy to any other monoclonal antibody;&#xD;
&#xD;
              32. Patients with other reasons that, in the opinion of the investigator, make it&#xD;
                  unsuitable to participate in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Panfeng Tan</last_name>
    <phone>+86 21 2067 1828</phone>
    <email>panfengt@hutch-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>secondline treatment in patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

